Spyre Therapeutics (SYRE) Non Operating Investment Income (2023)
Spyre Therapeutics posted quarterly Non Operating Investment Income of $30000.0 for Q4 2023, up 100.12% on a QoQ basis from -$25.4 million in Q3 2023.
Spyre Therapeutics (SYRE) has 1 years of Non Operating Investment Income data on file, last reported at $30000.0 in Q4 2023.
- For the quarter ending Q4 2023, Non Operating Investment Income changed N/A year-over-year to $30000.0; the trailing twelve-month figure through Dec 2024 stood at $30000.0 (up 100.04% YoY), and the FY2023 full-year result was -$83.5 million, changed N/A from the prior year.
- Non Operating Investment Income for Q4 2023 stood at $30000.0, up from -$25.4 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $30000.0 in Q4 2023 and bottomed at -$58.2 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Sep 30, 2023 | -25.40 Mn |
| Sep 30, 2023 | -25.40 Mn |
| Jun 30, 2023 | -58.20 Mn |
| Jun 30, 2023 | -58.20 Mn |